Risk of depressive symptom burden across central disorders of hypersomnolence: A nationwide multicenter study.
Central disorders of hypersomnolence (CDH) significantly impair quality of life, yet the burden of depressive symptoms across their subtypes remains poorly understood. We aimed to examine the clinical profiles and risk factors for depression burden among patients with narcolepsy type 1 (NT1), narcol…
Burden among participants with central disorders of hypersomnolence in six European countries.
Narcolepsy types 1 and 2 (NT1/NT2) and idiopathic hypersomnia (IH) are central disorders of hypersomnolence (CDHs) that significantly impact patients' quality of life (QoL). We investigated the recent medication use, comorbidities, and clinical burden among participants with CDHs from six European c…
Comparison of heart rate responses at respiratory event termination in children referred for assessment of hypersomnolence.
Adult studies have linked disorders of hypersomnolence to impaired heart rate (HR) control. We examined HR changes during obstructive and central respiratory events in children referred for assessment of hypersomnolence compared to controls. 20 children diagnosed with narcolepsy, 7 with idiopathic h…
Cerebrospinal fluid orexin testing in Australians with narcolepsy type 1.
A clinical diagnosis of narcolepsy type 1 can be challenging, particularly in relation to cataplexy. Despite its specificity, cerebrospinal fluid (CSF) orexin testing is under-utilised in Australasia. We describe the use of CSF orexin testing in 15 clinically indicated patients from two sleep centre…
Acute Modafinil Exposure Induces Neurobehavioral Alterations in Zebrafish: Implications for Off-Label Cognitive Enhancement.
Modafinil (2-(benzhydrylsulfinyl)acetamide) is a psychostimulant commonly prescribed for sleep disorders such as narcolepsy, excessive daytime sleepiness, and obstructive sleep apnea. Recently, its use has extended beyond clinical indications, with neurotypical individuals adopting it as a smart dru…
Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study.
Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) was a phase 4, prospective, multicenter, single-arm, open-label, multiple-cohort study of individuals with idiopathic hypersomnia or narcolepsy evaluating safety and effectiveness of low-sodium oxybate (LXB; Xyw…
Machine Learning for Diagnosis and Differentiation of Central Disorders of Hypersomnolence: A Systematic Review.
Central disorders of hypersomnolence (CDH) are, except for Narcolepsy Type 1 (NT1), difficult to diagnose and manage because of overlapping features and the lack of reliable biomarkers. Machine learning (ML) has the potential to improve diagnosis by detecting subtle physiological patterns and distin…
Assessment of readiness in the diagnosis and management of central disorders of hypersomnolence: A survey of sleep medicine program directors and fellowship graduates.
Central disorders of hypersomnolence (CDH), including narcolepsy, idiopathic hypersomnia, and recurrent hypersomnia, are rare conditions that pose challenges in sleep medicine fellowship training. Limited exposure to these disorders, variability in training experiences, and growing complexity of dia…